Symbols / ESLA Stock $1.58 -7.60% Estrella Immunopharma, Inc.
ESLA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Ratings
Current target
$1.58
Low
$12.00
High
$12.00
Mean
$12.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-09 | main | D. Boral Capital | Buy → Buy | $8 |
| 2026-01-28 | main | D. Boral Capital | Buy → Buy | $8 |
| 2025-11-03 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-08-12 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-06-03 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-05-29 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-02-21 | main | D. Boral Capital | Buy → Buy | $16 |
| 2025-02-18 | init | D. Boral Capital | — → Buy | $16 |
- Tesla lifts 2026 spending plans by a quarter as Musk funds AI and robotic dreams - Reuters hu, 23 Apr 2026 00
- Tesla stock adds nearly 8% as Elon Musk touts chip progress - CNBC Wed, 15 Apr 2026 07
- Tesla Might Have a Free Cash Flow Problem, Analyst Says. What It Means for the Stock. - Barron's Mon, 06 Apr 2026 07
- 1 Reason I'd Still Buy Tesla Stock Hand Over Fist and Never Sell - The Motley Fool Sun, 19 Apr 2026 13
- JPMorgan reiterates Tesla sell rating, $145 price target - qz.com Mon, 06 Apr 2026 07
- Estrella Immunopharma (ESLA) Management Strategy | Q1 2026: Below Expectations - Strong Sell - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 01
- How Tesla stock has moved after the last few earnings reports - MSN ue, 21 Apr 2026 13
- Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research - Yahoo Finance Mon, 23 Mar 2026 07
- Prediction: Tesla Stock Is a Buy Before 2029 Due to This $10 Trillion Opportunity - The Motley Fool Sat, 04 Apr 2026 07
- Tesla is developing a new smaller, cheaper EV, sources say - Reuters ue, 14 Apr 2026 07
- Estrella Immunopharma (ESLA) Stock Dividend Yield (Drifts Lower) 2026-04-20 - Open Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh Mon, 20 Apr 2026 15
- Tesla reports annual vehicle deliveries fell for second straight year, Q4 results miss forecasts - Yahoo Finance Fri, 02 Jan 2026 08
- Estrella Immunopharma (ESLA) Stock: Increase Exposure? (Dips) 2026-04-16 - Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La hu, 16 Apr 2026 21
- Tesla board made $3 billion via stock awards that dwarfed tech peers - Reuters Mon, 15 Dec 2025 08
- Estrella Immunopharma (ESLA) Stock Dividend Yield (Drifts Lower) 2026-04-20 - Most Discussed Stocks - Xã Vĩnh Công Mon, 20 Apr 2026 15
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
13.06
+78.69%
|
7.31
-34.23%
|
11.11
+559.47%
|
1.69
|
| Research And Development |
|
10.25
+149.42%
|
4.11
-60.68%
|
10.45
+652.37%
|
1.39
|
| Selling General And Administration |
|
2.81
-12.09%
|
3.20
+382.69%
|
0.66
+123.86%
|
0.30
|
| General And Administrative Expense |
|
2.81
-12.09%
|
3.20
+382.69%
|
0.66
+123.86%
|
0.30
|
| Other Gand A |
|
2.81
-12.09%
|
3.20
+382.69%
|
0.66
+123.86%
|
0.30
|
| Total Expenses |
|
13.06
+78.69%
|
7.31
-34.23%
|
11.11
+559.47%
|
1.69
|
| Operating Income |
|
-13.06
-78.69%
|
-7.31
+34.23%
|
-11.11
-559.47%
|
-1.69
|
| Total Operating Income As Reported |
|
-13.06
-78.69%
|
-7.31
+34.23%
|
-11.11
-559.47%
|
-1.69
|
| EBITDA |
|
-13.06
-78.69%
|
-7.31
+34.23%
|
-11.11
-559.47%
|
-1.69
|
| Normalized EBITDA |
|
-13.06
-78.69%
|
-7.31
+34.23%
|
-11.11
-559.47%
|
-1.69
|
| EBIT |
|
-13.06
-78.69%
|
-7.31
+34.23%
|
-11.11
-559.47%
|
-1.69
|
| Net Income |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Pretax Income |
|
-13.06
-78.69%
|
-7.31
+34.23%
|
-11.11
-559.47%
|
-1.69
|
| Tax Provision |
|
0.00
-48.43%
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Net Income From Continuing Operation Net Minority Interest |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Net Income From Continuing And Discontinued Operation |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Net Income Continuous Operations |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Normalized Income |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Net Income Common Stockholders |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Diluted EPS |
|
—
|
-0.27
+14.49%
|
-0.32
-559.47%
|
-0.05
|
| Basic EPS |
|
—
|
-0.27
+14.49%
|
-0.32
-559.47%
|
-0.05
|
| Basic Average Shares |
|
—
|
27.10
-23.00%
|
35.20
+0.00%
|
35.20
|
| Diluted Average Shares |
|
—
|
27.10
-23.00%
|
35.20
+0.00%
|
35.20
|
| Diluted NI Availto Com Stockholders |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Line Item | Trend | 2025-12-31 | 2024-06-30 |
|---|---|---|---|
| Total Assets |
|
3.18
-28.67%
|
4.45
|
| Current Assets |
|
1.68
-62.35%
|
4.45
|
| Cash Cash Equivalents And Short Term Investments |
|
1.38
-66.77%
|
4.17
|
| Cash And Cash Equivalents |
|
1.38
-66.77%
|
4.17
|
| Cash Financial |
|
—
|
—
|
| Receivables |
|
0.29
+1.35%
|
0.29
|
| Other Receivables |
|
0.29
+1.35%
|
0.29
|
| Prepaid Assets |
|
—
|
—
|
| Total Non Current Assets |
|
1.50
|
0.00
|
| Non Current Deferred Assets |
|
—
|
0.00
|
| Non Current Prepaid Assets |
|
1.50
|
0.00
|
| Total Liabilities Net Minority Interest |
|
13.54
+7394.72%
|
0.18
|
| Current Liabilities |
|
13.54
+7394.72%
|
0.18
|
| Payables And Accrued Expenses |
|
13.19
+7197.43%
|
0.18
|
| Payables |
|
0.63
+1037.69%
|
0.06
|
| Accounts Payable |
|
0.55
|
0.00
|
| Other Payable |
|
0.06
+16470.89%
|
0.00
|
| Current Accrued Expenses |
|
12.56
+9925.55%
|
0.13
|
| Total Tax Payable |
|
0.02
-65.98%
|
0.06
|
| Income Tax Payable |
|
0.00
-100.00%
|
0.04
|
| Other Current Liabilities |
|
0.36
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
| Other Non Current Liabilities |
|
—
|
—
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
0.00
|
| Stockholders Equity |
|
-10.37
-342.57%
|
4.27
|
| Common Stock Equity |
|
-10.37
-342.57%
|
4.27
|
| Capital Stock |
|
0.00
+5.14%
|
0.00
|
| Common Stock |
|
0.00
+5.14%
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
| Share Issued |
|
38.49
+5.12%
|
36.61
|
| Ordinary Shares Number |
|
37.97
+4.63%
|
36.29
|
| Treasury Shares Number |
|
0.52
+60.13%
|
0.32
|
| Additional Paid In Capital |
|
27.22
+12.83%
|
24.12
|
| Retained Earnings |
|
-36.99
-89.69%
|
-19.50
|
| Treasury Stock |
|
0.60
+68.82%
|
0.35
|
| Total Equity Gross Minority Interest |
|
-10.37
-342.57%
|
4.27
|
| Total Capitalization |
|
-10.37
-342.57%
|
4.27
|
| Working Capital |
|
-11.87
-377.67%
|
4.27
|
| Invested Capital |
|
-10.37
-342.57%
|
4.27
|
| Net Tangible Assets |
|
-10.37
-342.57%
|
4.27
|
| Tangible Book Value |
|
-10.37
-342.57%
|
4.27
|
| Notes Receivable |
|
—
|
0.00
|
| Preferred Stock Equity |
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-1.79
+88.89%
|
-16.07
-1102.61%
|
-1.34
+7.34%
|
-1.44
|
| Cash Flow From Continuing Operating Activities |
|
-1.79
+88.89%
|
-16.07
-1102.61%
|
-1.34
+7.34%
|
-1.44
|
| Net Income From Continuing Operations |
|
-13.06
-78.67%
|
-7.31
+34.21%
|
-11.11
-559.47%
|
-1.69
|
| Stock Based Compensation |
|
0.62
-48.19%
|
1.19
+191.67%
|
0.41
+215.15%
|
0.13
|
| Operating Gains Losses |
|
0.04
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
0.04
|
—
|
—
|
—
|
| Change In Working Capital |
|
10.62
+206.73%
|
-9.95
-206.22%
|
9.37
+8165.20%
|
0.11
|
| Change In Prepaid Assets |
|
0.43
+387.47%
|
-0.15
-118.00%
|
0.83
+200.00%
|
-0.83
|
| Change In Payables And Accrued Expense |
|
10.19
+203.96%
|
-9.80
-214.83%
|
8.54
+801.61%
|
0.95
|
| Change In Accrued Expense |
|
9.61
+53470.37%
|
-0.02
-181.82%
|
0.02
-97.67%
|
0.95
|
| Change In Payable |
|
0.58
+105.96%
|
-9.78
-214.92%
|
8.51
|
—
|
| Change In Account Payable |
|
0.55
+105.90%
|
-9.33
-211.27%
|
8.39
|
—
|
| Investing Cash Flow |
|
—
|
4.96
+1916.65%
|
-0.27
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
—
|
4.96
+1916.65%
|
-0.27
|
—
|
| Net Other Investing Changes |
|
—
|
4.96
+1916.65%
|
-0.27
|
—
|
| Financing Cash Flow |
|
2.25
-82.39%
|
12.79
|
0.00
-100.00%
|
5.53
|
| Cash Flow From Continuing Financing Activities |
|
2.25
-82.39%
|
12.79
|
0.00
-100.00%
|
5.53
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
|
0.00
|
—
|
| Issuance Of Debt |
|
—
|
0.30
|
0.00
|
—
|
| Repayment Of Debt |
|
—
|
-0.30
|
0.00
|
—
|
| Long Term Debt Issuance |
|
—
|
0.30
|
0.00
|
—
|
| Long Term Debt Payments |
|
—
|
-0.30
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
—
|
0.00
|
0.00
|
—
|
| Short Term Debt Issuance |
|
—
|
0.30
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
-0.30
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
2.37
+768.81%
|
-0.35
|
0.00
|
—
|
| Common Stock Payments |
|
-0.03
+91.69%
|
-0.35
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
-0.03
+91.69%
|
-0.35
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
0.01
|
| Net Other Financing Charges |
|
-0.12
-102.85%
|
4.13
|
—
|
—
|
| Changes In Cash |
|
0.47
-72.28%
|
1.69
+204.79%
|
-1.61
|
—
|
| Beginning Cash Position |
|
0.92
-63.01%
|
2.48
-39.36%
|
4.09
|
0.00
|
| End Cash Position |
|
1.38
-66.77%
|
4.17
+68.02%
|
2.48
-39.36%
|
4.09
|
| Free Cash Flow |
|
-1.79
+88.89%
|
-16.07
-1102.61%
|
-1.34
+7.34%
|
-1.44
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
-42.94%
|
0.00
|
0.00
|
0.00
|
| Change In Income Tax Payable |
|
-0.00
-2931.88%
|
-0.00
-104.31%
|
0.00
+191.70%
|
0.00
|
| Change In Tax Payable |
|
-0.00
-2931.88%
|
-0.00
-104.31%
|
0.00
+191.70%
|
0.00
|
| Common Stock Issuance |
|
2.40
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
2.40
-73.39%
|
9.02
|
0.00
-100.00%
|
5.00
|
| Net Preferred Stock Issuance |
|
—
|
9.02
|
0.00
-100.00%
|
5.00
|
| Preferred Stock Issuance |
|
—
|
9.02
|
0.00
-100.00%
|
5.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-18 View
- 8-K2026-01-13 View
- 8-K2026-01-06 View
- 8-K2025-12-04 View
- 10-Q2025-11-12 View
- 8-K2025-11-06 View
- 8-K2025-09-29 View
- 8-K2025-09-26 View
- 10-Q2025-08-12 View
- 8-K2025-08-07 View
- 8-K2025-06-05 View
- 8-K2025-06-03 View
- 8-K2025-05-29 View
- 10-Q2025-05-14 View
- 8-K2025-05-02 View
- 8-K2025-02-21 View
- 8-K2025-02-20 View
- 42025-02-14 View
- 42025-02-14 View
- 8-K2024-12-16 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|